Twist Bioscience Management
Management criteria checks 3/4
Twist Bioscience's CEO is Emily Leproust, appointed in Apr 2013, has a tenure of 11.58 years. total yearly compensation is $8.00M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $10.23M. The average tenure of the management team and the board of directors is 3.5 years and 8 years respectively.
Key information
Emily Leproust
Chief executive officer
US$8.0m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 11.6yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.5yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business
Sep 25
Investors Aren't Buying Twist Bioscience Corporation's (NASDAQ:TWST) Revenues
Aug 20Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Aug 04Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock
Jul 26We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth
Jun 10Twist Bioscience Corporation (NASDAQ:TWST) Shares Fly 29% But Investors Aren't Buying For Growth
May 04Twist Bioscience: NGS Is Taking Off
May 03Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Feb 27Twist Bioscience: Strong Performance In A Soft Market
Feb 07Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet
Jan 31We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate
Jan 22Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Dec 18Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans
Oct 05We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth
Jul 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$220m |
| Mar 31 2024 | n/a | n/a | -US$192m |
| Dec 31 2023 | n/a | n/a | -US$206m |
| Sep 30 2023 | US$8m | US$685k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$209m |
| Mar 31 2023 | n/a | n/a | -US$213m |
| Dec 31 2022 | n/a | n/a | -US$214m |
| Sep 30 2022 | US$6m | US$665k | -US$218m |
| Jun 30 2022 | n/a | n/a | -US$208m |
| Mar 31 2022 | n/a | n/a | -US$188m |
| Dec 31 2021 | n/a | n/a | -US$165m |
| Sep 30 2021 | US$1m | US$590k | -US$152m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$123m |
| Dec 31 2020 | n/a | n/a | -US$117m |
| Sep 30 2020 | US$7m | US$519k | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$147m |
| Mar 31 2020 | n/a | n/a | -US$147m |
| Dec 31 2019 | n/a | n/a | -US$141m |
| Sep 30 2019 | US$8m | US$477k | -US$108m |
| Jun 30 2019 | n/a | n/a | -US$96m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | n/a | n/a | -US$77m |
| Sep 30 2018 | US$525k | US$362k | -US$71m |
Compensation vs Market: Emily's total compensation ($USD8.00M) is about average for companies of similar size in the US market ($USD6.66M).
Compensation vs Earnings: Emily's compensation has increased whilst the company is unprofitable.
CEO
Emily Leproust (51 yo)
11.6yrs
Tenure
US$7,998,637
Compensation
Dr. Emily Marine Leproust, Ph.D. serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at GeneDx Holdings Corp. (formerly known as Sema4 Ho...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.6yrs | US$8.00m | 0.42% $ 10.2m | |
| President & COO | 2.1yrs | US$5.23m | 0.099% $ 2.4m | |
| Senior Vice President of Human Resources | 8.7yrs | US$2.49m | 0.045% $ 1.1m | |
| Senior VP of Advanced Development | 4.8yrs | US$2.82m | 0.44% $ 10.7m | |
| Chief Financial Officer | less than a year | no data | 0.0042% $ 101.1k | |
| VP & Chief Accounting Officer | 1.5yrs | no data | 0.012% $ 297.1k | |
| Chief Technology Officer | 3.8yrs | no data | no data | |
| Chief Scientific Officer | 3.8yrs | no data | no data | |
| Chief Information Officer | less than a year | no data | no data | |
| Senior VP | 3.2yrs | US$1.96m | 0.058% $ 1.4m | |
| Chief ESG Officer & Senior VP of Corporate Affairs | 3.8yrs | no data | no data | |
| Senior Vice President of Operations | 1.1yrs | no data | no data |
3.5yrs
Average Tenure
52yo
Average Age
Experienced Management: TWST's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.6yrs | US$8.00m | 0.42% $ 10.2m | |
| Senior VP of Advanced Development | 11.6yrs | US$2.82m | 0.44% $ 10.7m | |
| Independent Director | 11.1yrs | US$272.49k | 0.16% $ 3.9m | |
| Lead Independent Director | 10.3yrs | US$303.98k | 0.11% $ 2.7m | |
| Independent Director | 5.5yrs | US$284.99k | 0.030% $ 742.8k | |
| Independent Director | 8yrs | US$271.34k | 0.023% $ 565.5k | |
| Independent Director | 6.1yrs | US$284.99k | 0.020% $ 482.9k | |
| Independent Director | 3.3yrs | US$276.61k | 0.019% $ 452.5k | |
| Independent Director | 6.3yrs | US$269.99k | 0.043% $ 1.0m |
8.0yrs
Average Tenure
64yo
Average Age
Experienced Board: TWST's board of directors are considered experienced (8 years average tenure).